TARGETED THERAPIES Sunitinib in RCC-expanded access equals expanded benefit?

被引：3

作者：

Choueiri, Toni K. ^{[2
]}

Atkins, Michael B. ^{[1
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Div Hematol & Oncol, Boston, MA 02115 USA

[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2009年 / 6卷 / 12期

关键词：

RENAL-CELL CARCINOMA; INTERFERON-ALPHA;

D O I：

10.1038/nrclinonc.2009.170

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Sunitinib is a standard first-line therapy for patients with advanced or metastatic clear-cell renal cell carcinoma. In an expanded-access study, sunitinib has demonstrated clinical benefit with an acceptable safety profile in a population of patients that is representative of those seen in clinical practice.

引用

页码：679 / 680

页数：2

共 8 条

[1]

Treatment Selection for Patients With Metastatic Renal Cell Carcinoma [J].

Atkins, Michael B. ;

Choueiri, Toni K. ;

Cho, Daniel ;

Regan, Meredith ;

Signoretti, Sabina .

CANCER, 2009, 115 (10) :2327-2333

[2]

Optimizing Recent Advances in Metastatic Renal Cell Carcinoma [J].

Courtney, Kevin D. ;

Choueiri, Toni K. .

CURRENT ONCOLOGY REPORTS, 2009, 11 (03) :218-226

[3]

Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial [J].

Eisen, Tim ;

Oudard, Stephane ;

Szczylik, Cezary ;

Gravis, Gwenaelle ;

Heinzer, Hans ;

Middleton, Richard ;

Cihon, Frank ;

Anderson, Sibyl ;

Shah, Sonalee ;

Bukowski, Ronald ;

Escudier, Bernard .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (20) :1454-1463

[4]

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial [J].

Gore, Martin E. ;

Szczylik, Cezary ;

Porta, Camillo ;

Bracarda, Sergio ;

Bjarnason, Georg A. ;

Oudard, Stephane ;

Hariharan, Subramanian ;

Lee, Se-Hoon ;

Haanen, John ;

Castellano, Daniel ;

Vrdoljak, Eduard ;

Schoffski, Patrick ;

Mainwaring, Paul ;

Nieto, Alejandra ;

Yuan, Jinyu ;

Bukowski, Ronald .

LANCET ONCOLOGY, 2009, 10 (08) :757-763

[5]

Knox JJ, 2007, J CLIN ONCOL, V25

[6]

Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.2002.20.1.289

[7]

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [J].

Motzer, Robert J. ;

Hutson, Thomas E. ;

Tomczak, Piotr ;

Michaelson, M. Dror ;

Bukowski, Ronald M. ;

Rixe, Olivier ;

Oudard, Stephane ;

Negrier, Sylvie ;

Szczylik, Cezary ;

Kim, Sindy T. ;

Chen, Isan ;

Bycott, Paul W. ;

Baum, Charles M. ;

Figlin, Robert A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :115-124

[8]

Sunitinib in patients with metastatic renal cell carcinoma [J].

Motzer, Robert J. ;

Rini, Brian I. ;

Bukowski, Ronald M. ;

Curti, Brendan D. ;

George, Daniel J. ;

Hudes, Gary R. ;

Redman, Bruce G. ;

Margolin, Kim A. ;

Merchan, Jaime R. ;

Wilding, George ;

Ginsberg, Michelle S. ;

Bacik, Jennifer ;

Kim, Sindy T. ;

Baum, Charles M. ;

Michaelson, M. Dror .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (21) :2516-2524

← 1 →